Spatial profiling of non-small cell lung cancer provides insights into tumorigenesis and immunotherapy response.

In the above analysis, we found that B cell and M1 macrophage function varied in response to immune checkpoint inhibitor treatment, and to determine if this actually affected patient survival, we performed Kaplan–Meier survival analysis and found that median survival of the high B cell immunity group (749 days) was higher than that of the intermediate or low B cell immunity group (171 and 239 days) in the Severance cohort, although it did not reach statistical significance ( P = 0.057), and in the validation dataset, median survival was significantly increased in the high B cell immunity group (189 days) than the low B cell immunity group (89 days).

also in 111,027 other papers